Tags

Type your tag names separated by a space and hit enter

Recipient FK506 pretreatment regimens in rat small bowel transplantation: allograft survival, function, and systemic infection.
J Pediatr Surg. 2000 Nov; 35(11):1600-5.JP

Abstract

PURPOSE

Successful small bowel transplantation requires effective immunosuppression that preserves intestinal function but avoids opportunistic infection. This study aims to evaluate FK506 as a single immunosuppressant in different pretreatment regimens in a rat high responder strain combination.

METHODS

Lewis --> DA rat heterotopic small bowel transplantation was performed. Studied groups were (1) untreated control, n = 12; (2) FK-1, n = 8; (3) FK-3, n = 8. FK506 (2 mg/kg/d, intramuscularly) was given to the recipients for 1 day (FK-1) and 3 days (FK-3) before small bowel transplantation, followed by 2 weeks of subtherapeutic treatment (0.3 mg/kg/d, intramuscularly) after small bowel transplantation. Syngeneic small bowel transplantation also was performed (n = 8). FK blood levels, maltose absorption test, histology, and bacteriology were performed at different postoperative days.

RESULTS

Allograft survival was prolonged significantly with FK pretreatment, being more so in FK-3 group (FK-1, 22.2 +/- 1.5 d; FK-3, 40.7 +/- 14.1 d; control, 6.6 +/- 0.8 d; P< .01). In the first postoperative week, FK blood level was significantly higher in FK-3 group (19.8 +/- 1.5 ng/mL) than in FK-1 group (5.0 +/- 0.4 ng/mL; P < .05). There was no evidence of systemic infection in either FK-treated group. For maltose absorption, control allograft was abnormal on day 7 correlating to severely damaged intestinal architecture. In contrast, FK-treated allografts showed well-protected intestinal structure and normal absorption on days 7 and 21.

CONCLUSION

High FK506 blood levels in the first postoperative week, achieved with FK pretreatment, prolonged intestinal allograft survival and preserved intestinal structure and function without allowing systemic infection.

Authors+Show Affiliations

Department of Surgery, University of Hong Kong Medical Center, Queen Mary Hospital, Hong Kong SAR, PR China.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

11083432

Citation

Guo, W H., et al. "Recipient FK506 Pretreatment Regimens in Rat Small Bowel Transplantation: Allograft Survival, Function, and Systemic Infection." Journal of Pediatric Surgery, vol. 35, no. 11, 2000, pp. 1600-5.
Guo WH, Tian L, Yuen ZW, et al. Recipient FK506 pretreatment regimens in rat small bowel transplantation: allograft survival, function, and systemic infection. J Pediatr Surg. 2000;35(11):1600-5.
Guo, W. H., Tian, L., Yuen, Z. W., Chan, K. L., Wo, J. Y., Nicholls, G., Dallman, M., & Tam, P. K. (2000). Recipient FK506 pretreatment regimens in rat small bowel transplantation: allograft survival, function, and systemic infection. Journal of Pediatric Surgery, 35(11), 1600-5.
Guo WH, et al. Recipient FK506 Pretreatment Regimens in Rat Small Bowel Transplantation: Allograft Survival, Function, and Systemic Infection. J Pediatr Surg. 2000;35(11):1600-5. PubMed PMID: 11083432.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Recipient FK506 pretreatment regimens in rat small bowel transplantation: allograft survival, function, and systemic infection. AU - Guo,W H, AU - Tian,L, AU - Yuen,Z W, AU - Chan,K L, AU - Wo,J Y, AU - Nicholls,G, AU - Dallman,M, AU - Tam,P K, PY - 2000/11/18/pubmed PY - 2002/1/16/medline PY - 2000/11/18/entrez SP - 1600 EP - 5 JF - Journal of pediatric surgery JO - J Pediatr Surg VL - 35 IS - 11 N2 - PURPOSE: Successful small bowel transplantation requires effective immunosuppression that preserves intestinal function but avoids opportunistic infection. This study aims to evaluate FK506 as a single immunosuppressant in different pretreatment regimens in a rat high responder strain combination. METHODS: Lewis --> DA rat heterotopic small bowel transplantation was performed. Studied groups were (1) untreated control, n = 12; (2) FK-1, n = 8; (3) FK-3, n = 8. FK506 (2 mg/kg/d, intramuscularly) was given to the recipients for 1 day (FK-1) and 3 days (FK-3) before small bowel transplantation, followed by 2 weeks of subtherapeutic treatment (0.3 mg/kg/d, intramuscularly) after small bowel transplantation. Syngeneic small bowel transplantation also was performed (n = 8). FK blood levels, maltose absorption test, histology, and bacteriology were performed at different postoperative days. RESULTS: Allograft survival was prolonged significantly with FK pretreatment, being more so in FK-3 group (FK-1, 22.2 +/- 1.5 d; FK-3, 40.7 +/- 14.1 d; control, 6.6 +/- 0.8 d; P< .01). In the first postoperative week, FK blood level was significantly higher in FK-3 group (19.8 +/- 1.5 ng/mL) than in FK-1 group (5.0 +/- 0.4 ng/mL; P < .05). There was no evidence of systemic infection in either FK-treated group. For maltose absorption, control allograft was abnormal on day 7 correlating to severely damaged intestinal architecture. In contrast, FK-treated allografts showed well-protected intestinal structure and normal absorption on days 7 and 21. CONCLUSION: High FK506 blood levels in the first postoperative week, achieved with FK pretreatment, prolonged intestinal allograft survival and preserved intestinal structure and function without allowing systemic infection. SN - 0022-3468 UR - https://www.unboundmedicine.com/medline/citation/11083432/Recipient_FK506_pretreatment_regimens_in_rat_small_bowel_transplantation:_allograft_survival_function_and_systemic_infection_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0022-3468(00)66700-3 DB - PRIME DP - Unbound Medicine ER -